Literature DB >> 15765786

Isolated hyperkalemia associated with cyclosporine administration in allogeneic stem cell transplantation for renal cell carcinoma.

Akiyoshi Takami1, Hidesaku Asakura, Hiroyuki Takamatsu, Hirohito Yamazaki, Masahisa Arahata, Tomoe Hayashi, Masami Shibayama, Michiko Orito, Tomotaka Yoshida, Mikio Namiki, Shinji Nakao.   

Abstract

Two patients with advanced renal cell carcinoma underwent allogeneic hematopoietic stem cell transplantation and received cyclosporine (CSP) as part of their immunosuppressive therapy. Despite adequate renal function, both patients developed hyperkalemia. CSP was the only pharmaceutical agent to which this electrolyte abnormality could be attributed. Evaluation of renal tubule function suggested that CSP-associated isolated hyperkalemia resulted from tubular resistance to aldosterone. We propose that the presence of a single functional kidney may be a risk factor for isolated hyperkalemia due to CSP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765786     DOI: 10.1532/ijh97.04113

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients.

Authors:  J P Bantle; K A Nath; D E Sutherland; J S Najarian; T F Ferris
Journal:  Arch Intern Med       Date:  1985-03

2.  Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.

Authors:  R W Childs; E Clave; J Tisdale; M Plante; N Hensel; J Barrett
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

3.  Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine.

Authors:  K S Kamel; J H Ethier; S Quaggin; A Levin; S Albert; E J Carlisle; M L Halperin
Journal:  J Am Soc Nephrol       Date:  1992-02       Impact factor: 10.121

4.  Hyperkalemia associated with cyclosporine (CsA) use in bone marrow transplantation.

Authors:  D R Fleming; R Ouseph; J Herrington
Journal:  Bone Marrow Transplant       Date:  1997-02       Impact factor: 5.483

5.  [Hyperkalemia in a cyclosporine A-treated allogeneic bone marrow transplant recipient].

Authors:  N Kinugawa; Y Okimoto; S Ota
Journal:  Rinsho Ketsueki       Date:  1992-01

6.  Effects of cyclosporine on tubular acidification function in patients with idiopathic uveitis.

Authors:  S Aguilera; G Deray; H Desjobert; M Benhmida; P Le Hoang; C Jacobs
Journal:  Am J Nephrol       Date:  1992       Impact factor: 3.754

7.  Extrarenal effect of cyclosporine A on potassium homeostasis in renal transplant recipients.

Authors:  Y Pei; R Richardson; C Greenwood; P Y Wong; A Baines
Journal:  Am J Kidney Dis       Date:  1993-08       Impact factor: 8.860

Review 8.  Cyclosporine nephrotoxicity.

Authors:  Emmanuel A Burdmann; Takeshi F Andoh; Luis Yu; William M Bennett
Journal:  Semin Nephrol       Date:  2003-09       Impact factor: 5.299

9.  Hyperkalaemia in cyclosporin-treated renal allograft recipients.

Authors:  D Adu; J Turney; J Michael; P McMaster
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

10.  The effect of conversion from cyclosporin to azathioprine on renin-containing cells in renal allograft biopsies.

Authors:  D S Gardiner; M A Watson; B J Junor; J D Briggs; I A More; G B Lindop
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

View more
  1 in total

1.  Electrolytes Disturbance and Cyclosporine Blood Levels among Kidney Transplant Recipients.

Authors:  B Einollahi; E Nemati; Z Rostami; M Teimoori; A R Ghadian
Journal:  Int J Organ Transplant Med       Date:  2012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.